Status:
COMPLETED
Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325
Lead Sponsor:
AstraZeneca
Conditions:
Anxiety Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.
Eligibility Criteria
Inclusion
- Signed informed consent before any study-related procedures start.
- The patient is previously diagnosed with Generalized Anxiety Disorder.
- The patient has a HADS-A (anxiety) score ≥10 at both screening and randomization.
Exclusion
- Patient has a lifetime history of schizophrenia or other psychotic disorders
- Patient has a history of seizures or seizure disorder.
- Patient is pregnant or breast feeding.
- Patient has received electroconvulsive treatment (ECT) in the past.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
369 Patients enrolled
Trial Details
Trial ID
NCT00807937
Start Date
December 1 2008
End Date
May 1 2009
Last Update
October 8 2010
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Mesa, Arizona, United States
2
Research Site
Little Rock, Arkansas, United States
3
Research Site
Carson, California, United States
4
Research Site
Escondido, California, United States